BBBernt Tore Bra°Tane

Bernt Tore Bra°Tane

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bernt Tore Bra°Tane has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • James Bouley

    From the Department of Neurology (B.T.B., J.B., M.F.), University of Massachusetts Medical School, Worcester, MA; and Toronto Western Research Institute (H.C., D.J.C., M.T.), University Health Network, Toronto, Ontario, Canada

    4 shared publications
  • Marc Fisher

    From the Department of Neurology (B.T.B., J.B., M.F.), University of Massachusetts Medical School, Worcester, MA; and Toronto Western Research Institute (H.C., D.J.C., M.T.), University Health Network, Toronto, Ontario, Canada

    4 shared publications
  • Nils Henninger

    Department of neurology, University of Massachusetts Chan Medical School, Worcester, MA, USA

    3 shared publications
  • Birgul Bastan

    From the Department of Neurology (B.T.B., J.B., B.B., N.H., M.F.), University of Massachusetts Medical School, Worcester, Mass, and Molecular Neurology (A.S.), Sygnis Bioscience GmbH & Co KG, Heidelberg, Germany

    2 shared publications
  • Kenneth M. Sicard

    A Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA

    2 shared publications
  • Ahmad Moussa

    1 shared publication

Latest Publications

  • Neuroprotection by Freezing Ischemic Penumbra Evolution Without Cerebral Blood Flow Augmentation With a Postsynaptic Density-95 Protein Inhibitor

    by Bernt T. Bråtane, Hong Cui, Douglas J. Cook, James Bouley, Michael Tymianski, Marc Fisher

    Background and Purpose—: The purpose of this study was to determine whether neuroprotection is feasible without cerebral blood flow augmentation in experimental permanent middle cerebral artery occlusion. Methods—: Rats were subjected to permanent middle cerebral artery occlusion by the suture occlusion method and were treated 1 hour thereafter with a single 5-minute intravenous infusion of the postsynaptic density-95 protein inhibitor Tat-NR2B9c (7.5 mg/kg) or saline (n=8/group). Arterial spin-labeled perfusion-weighted MRI and diffusion weighted MRI were obtained with a 4.7-T Bruker system at 30, 45, 70, 90, 120, 150, and 180 minutes postmiddle cerebral artery occlusion to determine cerebral blood flow and apparent diffusion coefficient maps, respectively. At 24 hours, animals were neurologically scored (0 to 5), euthanized, and the brains stained with 2–3-5-triphenyl tetrazolium chloride to ascertain infarct volumes corrected for edema. Additionally, the effects of Tat-NR2B9c on adenosine 5′-triphosphate levels were measured in vitro in neurons subjected to oxygen–glucose deprivation. Results—: Final infarct volume was decreased by 30.3% in the Tat-NR2B9c-treated animals compared with controls ( P =0.028). There was a significant improvement in 24 hours neurological scores in the Tat-NR2B9c group compared with controls, 1.8±0.5 and 2.8±1.0, respectively ( P =0.021). Relative to controls, Tat-NR2B9c significantly attenuated diffusion-weighted imaging lesion growth and preserved the diffusion-weighted imaging/perfusion-weighted imaging mismatch (ischemic penumbra) without affecting cerebral blood flow in the ischemic core or penumbra. Tat-NR2B9c treatment of primary neuronal cultures resulted in 26% increase in cell viability and 34% greater adenosine 5′-triphosphate levels after oxygen–glucose deprivation. Conclusions—: Preservation of adenosine 5′-triphosphate levels in vitro and neuroprotection in permanent middle cerebral artery occlusion in rats is achievable without cerebral blood flow augmentation using a postsynaptic density-95 protein inhibitor.


  • Visualization of Clot Lysis in a Rat Embolic Stroke Model

    by Ronn P. Walvick, Bernt T. Bråtane, Nils Henninger, Kenneth M. Sicard, James Bouley, Zhanyang Yu, Eng Lo, Xiaoying Wang, Marc Fisher

    Background and Purpose—: The purpose of this study was to develop a novel MRI method for imaging clot lysis in a rat embolic stroke model and to compare tissue plasminogen activator (tPA)-based clot lysis with and without recombinant Annexin-2 (rA2). Methods—: In experiment 1 we used in vitro optimization of clot visualization using multiple MRI contrast agents in concentrations ranging from 5 to 50 μL in 250 μL blood. In experiment 2, we used in vivo characterization of the time course of clot lysis using the clot developed in the previous experiment. Diffusion, perfusion, angiography, and T1-weighted MRI for clot imaging were conducted before and during treatment with vehicle (n=6), tPA (n=8), or rA2 plus tPA (n=8) at multiple time points. Brains were removed for ex vivo clot localization. Results—: Clots created with 25 μL Magnevist were the most stable and provided the highest contrast-to-noise ratio. In the vehicle group, clot length as assessed by T1-weighted imaging correlated with histology ( r =0.93). Clot length and cerebral blood flow-derived ischemic lesion volume were significantly smaller than vehicle at 15 minutes after treatment initiation in the rA2 plus tPA group, whereas in the tPA group no significant reduction from vehicle was observed until 30 minutes after treatment initiation. The rA2 plus tPA group had a significantly shorter clot length than the tPA group at 60 and 90 minutes after treatment initiation and significantly smaller cerebral blood flow deficit than the tPA group at 90 minutes after treatment initiation. Conclusions—: We introduce a novel MRI-based clot imaging method for in vivo monitoring of clot lysis. Lytic efficacy of tPA was enhanced by rA2.


  • Open Access

    Characterization of Gadolinium-Based Dynamic Susceptibility Contrast Perfusion Measurements in Permanent and Transient MCAO Models with Volumetric Based Validation by CASL

    by Bernt T Bråtane, Ronn P Walvick, Claire Corot, Eric Lancelot, Marc Fisher

    Perfusion imaging is crucial in imaging of ischemic stroke to determine ‘tissue at risk’ for infarction. In this study we compared the volumetric quantification of the perfusion deficit in two rat middle-cerebral-artery occlusion (MCAO) models using two gadolinium-based contrast agents (P1152 (Guerbet) and Magnevist (Bayer-Schering, Pittsburgh, PA, USA)) as compared with our well established continuous arterial spin labeling (CASL) perfusion imaging technique. Animals underwent either permanent MCAO or transient MCAO with 80-min reperfusion. Imaging was performed at four different time points after MCAO. A region-of-interest (ROI) analysis of the subregions of the ischemic zone (core, penumbra, transient reversal (TR), and sustained reversal (SR)) using P1152 showed significant reduction in blood flow in the core and TR subregions relative to the penumbral and SR subregions while occluded. After reperfusion, a significant increase in blood flow was recorded at all time points after reperfusion in all regions except TR. From the ROI analysis the threshold for the penumbra was determined to be −62±11% and this value was subsequently used for quantification of the volumetric deficit. The ischemic volume as defined by dynamic susceptibility contrast (DSC), was only statistically different from the CASL-derived ischemic volume when using Magnevist at post-reperfusion time points.


  • Granulocyte-Colony Stimulating Factor Delays PWI/DWI Mismatch Evolution and Reduces Final Infarct Volume in Permanent-Suture and Embolic Focal Cerebral Ischemia Models in the Rat

    by Bernt T. Bråtane, James Bouley, Armin Schneider, Birgul Bastan, Nils Henninger, Marc Fisher, Schneider A, Schäbitz W, Ringelstein E, Pösel C, et al.

    Background and Purpose— Granulocyte-colony stimulating factor (G-CSF) is used clinically to attenuate neutropenia after chemotherapy. G-CSF acts as a growth factor in the central nervous system, counteracts apoptosis, and is neuroprotective in rodent transient ischemia models. Methods— We assessed the effect of G-CSF on ischemic lesion evolution in a rat permanent-suture occlusion model with diffusion- and perfusion-weighted magnetic resonance imaging and the neuroprotective effect of G-CSF in a rat embolic stroke model. Results— With a constant perfusion deficit, vehicle-treated animals showed an expanding apparent diffusion coefficient lesion volume that matched the perfusion deficit volume at ≈3 hours, with the 24-hour infarct volume equivalent to the perfusion deficit. In G-CSF–treated rats, the apparent diffusion coefficient lesion volume did not increase after treatment initiation, and the infarct volume at 24 hours reflected the initial apparent diffusion coefficient lesion volume. In the embolic model, we observed a significant decrease in infarct volume in G-CSF–treated animals compared with the vehicle-treated group. Conclusions— These results confirm the potent neuroprotective activity of G-CSF in different focal ischemia models. The magnetic resonance imaging data demonstrate that G-CSF preserved the perfusion/diffusion mismatch.


  • Ischemic lesion volume determination on diffusion weighted images vs. apparent diffusion coefficient maps

    by Bernt Tore Bra°Tane, Birgul Bastan, Marc Fisher, James Bouley, Nils Henninger